PharmaCyte Biotech Inc (PMCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has a cash flow conversion efficiency ratio of -0.040x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.39 Million) by net assets ($34.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PharmaCyte Biotech Inc (PMCB) total market value for the company's overall valuation and market capitalisation.
PharmaCyte Biotech Inc - Cash Flow Conversion Efficiency Trend (2004–2026)
This chart illustrates how PharmaCyte Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PharmaCyte Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaCyte Biotech Inc ranked by their cash flow conversion efficiency. Explore PharmaCyte Biotech Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
-0.388x |
|
Ho Hup Construction Company
KLSE:5169
|
0.003x |
|
Project Planning Service Public Company Limited
BK:PPS
|
-0.045x |
|
Krakatoa Resources Ltd
AU:KTA
|
-0.524x |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
-0.038x |
|
BIRD RIVER RES. INC.
F:1Q1A
|
N/A |
|
GB Group plc
LSE:GBG
|
0.047x |
|
Azucar Minerals Ltd
V:AMZ
|
-0.360x |
Annual Cash Flow Conversion Efficiency for PharmaCyte Biotech Inc (2004–2026)
The table below shows the annual cash flow conversion efficiency of PharmaCyte Biotech Inc from 2004 to 2026. View PharmaCyte Biotech Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | $34.98 Million | $-5.15 Million | -0.147x | -156.65% |
| 2025-04-30 | $51.89 Million | $-2.98 Million | -0.057x | -5.41% |
| 2024-04-30 | $39.51 Million | $-2.15 Million | -0.054x | -4.32% |
| 2023-04-30 | $72.69 Million | $-3.79 Million | -0.052x | -13.98% |
| 2022-04-30 | $89.92 Million | $-4.12 Million | -0.046x | +90.82% |
| 2021-04-30 | $6.68 Million | $-3.33 Million | -0.499x | -8.53% |
| 2020-04-30 | $5.09 Million | $-2.34 Million | -0.459x | +19.54% |
| 2019-04-30 | $5.04 Million | $-2.88 Million | -0.571x | +35.14% |
| 2018-04-30 | $5.77 Million | $-5.08 Million | -0.881x | -113.24% |
| 2017-04-30 | $8.09 Million | $-3.34 Million | -0.413x | +38.03% |
| 2016-04-30 | $6.52 Million | $-4.35 Million | -0.666x | +13.26% |
| 2015-04-30 | $5.94 Million | $-4.56 Million | -0.768x | -339.64% |
| 2014-04-30 | $8.94 Million | $-1.56 Million | -0.175x | -141.24% |
| 2013-04-30 | $-921.46K | $-390.43K | 0.424x | +177.77% |
| 2012-04-30 | $-1.70 Million | $-259.29K | 0.153x | +84.84% |
| 2011-04-30 | $-2.73 Million | $-225.23K | 0.083x | -83.47% |
| 2010-04-30 | $-1.95 Million | $-974.06K | 0.499x | +231.54% |
| 2009-04-30 | $3.12 Million | $-1.19 Million | -0.380x | -136.92% |
| 2008-04-30 | $7.44 Million | $-1.19 Million | -0.160x | -95.28% |
| 2007-04-30 | $4.29 Million | $-351.60K | -0.082x | +66.25% |
| 2006-04-30 | $4.41 Million | $-1.07 Million | -0.243x | -111.25% |
| 2005-04-30 | $-1.30 Million | $-2.80 Million | 2.160x | +49.95% |
| 2004-04-30 | $-153.43K | $-221.03K | 1.441x | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more